How expensive it may be drugs? The pharmaceutical industry is under increasing pressure to justify given the cost of over 100’000 Swiss francs for combination therapies in cancer.
The price of drugs sets the Federal office of public health (BAG). The SRF broadcast “Rundschau” from Wednesday to disclose with reference to an example of how the negotiations run. According to the documents, has released the BAG under the freedom of information act, reached a price of Roche a much higher Drugs than the Federal Agency had originally sought.
A pack of cancer by means of Perjeta should be free to enter the market in 2013, according to the Federal 1850 francs. Roche was a price of 3450 Swiss francs. In the “Rundschau” has now been made subject to the reproach that the BAG can be when setting the price for Roches cancer drug under pressure have put. The BAG. “The fact is that the pricing for Perjeta is a success.” Thus, the agents in the combination therapy was more favorable than the effective quenched and tempered prices abroad. Speaker Thomas Christians but also to the SRF, the BAG was under pressure from the industry. The Federal office is in 60 cases before the court, because there is no price agreement has been made.
Federal Council waving off
The non-governmental organisation Public Eye takes the shipment to the occasion to reiterate their demand that the government must obtain in the case of Perjeta, a compulsory license. In the case of a compulsory license, the pharmaceutical companies will be forced to leave against compensation of its agents by a third party to produce, with the aim to lower the price and the supply of the population so as to ensure.
SP-national councillor Angelo Barrile had filed in June, a corresponding advance. The Federal Council wants to know anything. “A discharge in respect of the cost of health care through compulsory licensing of expensive new medicines from the point of view of the Federal Council in the current Patent remedies law, it is not possible”, it means in his opinion. So also the holder of a compulsory license for the approval of self-manufactured would need to rise By means of “all clinical data and independently of the admission authority, which can take several years and is costly”.
Federal government to keep prices in check by threats deep
This Argument will invalidate the Public Eye with an opinion of Professor Valérie Junod, University of Geneva. Accordingly, the holder of the compulsory license may request the data necessary for authorisation from the patent holder, Roche, should find the patent court is a “public interest” in a compulsory license. Otherwise, could infringe Roche’s anti-trust law, because it exploits its dominant Position.
pharmaceutical connoisseurs consider it to be illusory, that the government is received via a compulsory licence, the risk to be for the manufacture of a medicament to be responsible. According to the Public Eye, the campaign, therefore, the primary issue is that the Federal Council should threaten them with the means of a compulsory license to reduce the price of the wishes of the pharmaceutical industry.
(editing Tamedia)
Created: 30.01.2019, 20:28 PM
